# A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

> **NCT03657095** · PHASE3 · TERMINATED · sponsor: **Lung Biotechnology PBC** · enrollment: 112 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Esuberaprost
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03657095
- **Lead sponsor:** Lung Biotechnology PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-07-20
- **Final completion:** 2019-07-20
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.
- **Last updated:** 2020-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657095, "A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03657095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*